|
- 品牌：爱必信(absin)
- 产地：中国
- 货号：abs812984
- cas：84687-43-4
- 价格： ￥533/瓶
- 发布日期： 2022-04-07
- 更新日期： 2025-09-19
| 产地 | 中国 |
| 品牌 | 爱必信(absin) |
| 货号 | abs812984 |
| 用途 | 见爱必信官网 |
| 英文名称 | 见爱必信官网 |
| 包装规格 | 10mg,10mg,10mg,50mg,50mg,50mg,100mg,100mg,100mg |
| 纯度 | >98%% |
| CAS编号 | 84687-43-4 |
| 别名 | 黄芪甲苷IV;黄芪甲苷 |
| 是否进口 | 否 |
|
公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
抑制剂描述: 产品名称:Astragaloside IV 产品别名:见爱必信官网 英文别名:Astragaloside IV 靶点:Triterpenoids CAS:84687-43-4;83207-58-3 纯度:>98% 外观:见爱必信官网 保存方法:Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. 描述: 溶解性:DMSO :100 mg/mL (127.39 mM) 体外研究:
Astragaloside IV (10, 20, 40 ng/mL) inhibits NSCLC cell growth, whereas low concentrations of astragaloside IV (1, 2.5, 5 ng/mL) has no obvious cytotoxicity on cell viability. Moreover, combined treatment with astragaloside IV significantly increases chemosensitivity to cisplatin in NSCLC cells. On the molecular level, astragaloside IV co-treatment significantly inhibits the mRNA and protein levels of B7-H3 in the presence of cisplatin. Astragaloside IV inhibits the viability and invasive potential of MDA-MB-231 breast cancer cells, suppresses the activation of the mitogen activated protein kinase (MAPK) family members ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2 and -9. 体内研究:Astragaloside IV (10, 20 mg/kg, p.o.) exhibits a potent ability to prevent cognitive deficits induced by transient cerebral ischemia and reperfusion. Astragaloside IV (10 mg/kg) and Astragaloside IV (20 mg/kg) can significantly decrease the levels of these cytokines compared to the Model group. Astragaloside IV significantly inhibits the level of TLR4 and its downstream proteins, suggesting that both MyD88-dependent and -independent pathways play important roles in the anti-inflammatory effects of Astragaloside IV. Astragaloside IV attenuates NLRP3 and cleaved-caspase-1 expression, and reduces Iba1 protein expression. In the mice model, the high-dose astragaloside IV group has a significant increase in the 48-hour survival rate [60% (9/15) vs 13.3% (2/15), P < 0.05], significant reductions in the serum ALT and AST levels (P < 0.01), and significant reductions in liver histopathological indices and the degree of apoptosis of hepatocytes (P < 0.01), as well as a significant reduction in the content of MDA in liver homogenate (P < 0.01) and a significant increase in the activity of SOD.
产品信息订购:
|
- 手机：18438616290